Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has fully repaid its 2.75% convertible bonds (ISIN CH0305398148), which were due on December 23, 2022, with an outstanding nominal amount of CHF 113.8 million. As there was no conversion, no shares have been issued and the share capital remains unchanged.
Adesh Kaul, Chief Financial Officer, stated: “We are very pleased to have fully redeemed the 2022 convertible bonds. As announced, we have thus successfully reduced our debt-level without diluting our shareholders, based on the growing cash flows from our marketed drugs and our strong financial prospects.”
https://www.biospace.com/article/releases/basilea-announces-repayment-of-2022-convertible-bonds/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.